Christoffer Vinther Sørensen

Y-king Biologics - A universal platform for enhancing tomorrow's biologics

From left to right: Andreas Hougaard Laustsen-Kiel, and Christoffer Vinther Sørensen.

Applicant

Christoffer Vinther Sørensen.

Project drescription

At Y-king Biologics, we are pioneering a proprietary platform technology that allows us to introduce pH-dependent antigen binding properties into any antibody-based therapeutic without altering the critical antibody-antigen binding interface. This technology offers new functionalities, such as improved tumor targeting for cancer therapies, reducing damage to healthy tissues, or enablingthe facile development of sweeping antibodies with unprecedented potency. Our platform both facilitates the development of biobetters and entirely new antibody-based biologics.

Institution

Technical University of Denmark.